KISQALI (ribociclib) Patient Assistance Program
Don’t let the high cost of brand specialty CDK4/6 inhibitor therapy disrupt your treatment. We help eligible patients access Kisqali (ribociclib) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey.
- Annual Re-certification And Refills Management
- Medicare Part D Patients Accepted
HIPAA Compliant
BBB Accredited
Secure Website
Key Takeaways:
- Kisqali (ribociclib) is FDA-approved in combination with an aromatase inhibitor or fulvestrant for hormone receptor-positive (HR+), HER2-negative advanced or metastatic breast cancer, and in combination with an aromatase inhibitor for adjuvant treatment of HR+/HER2- early breast cancer at high risk of recurrence. It is a CDK4/6 inhibitor.
- Without assistance, Kisqali costs commonly run approximately $13,500–$16,000 per 30-day supply.
- Through AffordMyPrescriptions, qualifying patients can access Kisqali for a flat $69.95 per month — our advocacy team manages the entire enrollment, refills, and renewal process.
- There is no generic Kisqali in the U.S. as of 2026. Other CDK4/6 inhibitors include palbociclib (Ibrance) and abemaciclib (Verzenio). Among CDK4/6 inhibitors in metastatic HR+/HER2- breast cancer, Kisqali has shown the most consistent overall survival benefit across multiple phase III trials.
What Is Kisqali Prescription Assistance Program?
The Kisqali Prescription Assistance Program is a manufacturer-sponsored initiative that provides Kisqali at little or no medication cost to qualifying patients based on income and insurance status. The program is designed for HR+/HER2- breast cancer patients who are uninsured or underinsured, as well as Medicare Part D beneficiaries.
Navigating the program on your own means dealing with eligibility verification, oncology coordination, prior-authorization documentation, specialty pharmacy logistics, and renewal deadlines.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your enrollment, from initial application through ongoing refill coordination and re-certification.
Pharmacy Price Comparison
- Without assistance, Kisqali costs roughly $13,500–$16,000/month. A Patient Assistance Program is the meaningful path forward — if you qualify:
| Pharmacy(With Coupon) | PrIce (30-Day)* | You Save W/ Us |
|---|---|---|
| Walgreens | ~$15,500 | Save ~$15,430/mo |
| CVS Pharmacy | ~$16,000 | Save ~$15,930/mo |
| Walmart | ~$14,000 | Save ~$13,930/mo |
| Costco | ~$13,700 | Save ~$13,630/mo |
Specialty Pharmacy | ~$14,500 | Save ~$14,430/mo |
*Just a heads-up — retail prices are estimates based on public data and vary by pharmacy. AffordMyPrescriptions Advocacy Service bypasses this by using drug manufacturer programs to secure your medication directly at no cost or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Kisqali Prescription Program?
The Patient Assistance Program is free to apply for and provides Kisqali at no medication cost if approved. Our $69.95/month service covers full advocacy.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.
We Advocate
Our specialists help gather documentation, complete applications, and coordinate with program providers.
Receive Medication
Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Kisqali:
Limitations of Coupons
- Prices fluctuate — savings aren’t guaranteed month-to-month
- Copay accumulators may prevent savings from counting toward deductible
- Coupon cards expire and require constant renewal
Still $13,500–$16,000 per month even with the best discount
- Can’t be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
- Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
- Medication supplied directly through the assistance program
- We manage all paperwork, refills, and annual renewals
- If denied, we explore alternative savings on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Kisqali assistance.
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Kisqali Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or A Medicare Part D Beneficiary
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Not sure if you qualify? Our pre-qualification check is completely free. If we can’t help, you won’t be charged.
Understanding Kisqali:
Kisqali (ribociclib) is a once-daily oral selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6) used in combination with endocrine therapy for hormone receptor-positive (HR+), HER2-negative advanced and early breast cancer.
How Kisqali Works:
HR+/HER2- breast cancer cells rely on the CDK4/6 pathway and hormone signaling to grow and progress through the cell cycle. Kisqali works by selectively blocking CDK4 and CDK6, which stops cell-cycle progression and arrests cancer cells. When combined with endocrine therapy, this inhibition significantly extends progression-free and overall survival in metastatic cases. In high-risk, early-stage breast cancer, adding Kisqali to an aromatase inhibitor effectively reduces the risk of recurrence.
Form and use:
Kisqali is an oral medication taken once daily with or without food. It follows a 28-day cycle consisting of 21 days on the medication followed by 7 days off. The standard starting dose is 600 mg per day, taken as three 200 mg tablets. To treat the cancer effectively, it must be combined with endocrine therapies like fulvestrant, letrozole, or anastrozole.
Generic availability:
As of 2026, there is no generic version of Kisqali available in the United States. Other alternative CDK4/6 inhibitors include palbociclib (Ibrance) and abemaciclib (Verzenio). While Ibrance shares a similar 21 days on, 7 days off schedule, Kisqali has demonstrated the most consistent overall survival benefits in metastatic cases. In contrast, Verzenio is taken continuously and has unique efficacy in node-positive early breast cancer, though it causes more gastrointestinal side effects.
Warnings:
Kisqali carries major warnings for heart-related risks like QT prolongation, requiring routine ECG monitoring and electrolyte correction. Patients must also be monitored closely via blood tests for liver toxicity (LFTs) and low white blood cell counts (neutropenia). Other serious risks include severe skin reactions, lung inflammation (interstitial lung disease), and embryo-fetal toxicity. Additionally, it has significant drug interactions with CYP3A inhibitors/inducers and other QT-prolonging medications.
FAQ (Frequently Asked Questions)
How Much Does Kisqali Cost Without Insurance?
Kisqali costs approximately $13,500–$16,000 per 30-day supply. Through AffordMyPrescriptions, qualifying patients receive Kisqali at no medication cost — our $69.95 monthly fee covers full advocacy and program management.
How Is Kisqali Different From Ibrance Or Verzenio?
All three are CDK4/6 inhibitors used with endocrine therapy in HR+/HER2- breast cancer. Kisqali (ribociclib) — dosed 21 days on / 7 off; consistent overall survival benefit in metastatic disease across MONALEESA trials. Ibrance (palbociclib) — same dosing schedule; PFS benefit but mixed OS data in metastatic trials. Verzenio (abemaciclib) — dosed continuously; uniquely approved for adjuvant high-risk node-positive HR+/HER2- early breast cancer; more GI side effects (diarrhea). The choice between them depends on patient preferences, toxicity profile, and the specific clinical setting.
What Is The Schedule For Kisqali?
Kisqali is taken once daily for 3 weeks, then no Kisqali for 1 week (a 28-day cycle). This on/off schedule helps neutrophil counts recover during the off week. You continue your daily endocrine therapy (aromatase inhibitor or fulvestrant) throughout — only Kisqali is paused during the off week.
Why Do I Need ECG Monitoring On Kisqali?
Kisqali can prolong the QT interval. Baseline ECG is obtained before starting; ECG is repeated around day 14 of cycle 1 and at the start of cycle 2; additional ECGs as clinically indicated. Electrolytes (potassium, magnesium, calcium) should be monitored and corrected. Avoid other QT-prolonging drugs where possible — discuss every medication and supplement with your pharmacist.
What About Low Blood Counts?
Neutropenia is the most common dose-limiting toxicity with CDK4/6 inhibitors. CBC is checked every 2 weeks for the first 2 cycles, then before each new cycle, and as clinically indicated. Severe neutropenia may require dose interruption or reduction. Most CDK4/6-induced neutropenia is rapidly reversible during the off week and not associated with infection risk as severe as chemotherapy-induced neutropenia.
Can I Get Kisqali Through The PAP If I Have Medicare?
Yes. Medicare Part D beneficiaries can typically qualify, especially if you face specialty-tier copays. The manufacturer’s commercial copay savings program is reserved for commercially insured patients only — but the underlying PAP supports Medicare patients who meet income criteria.
What If My Application Is Denied?
If denied, we explore alternatives — switching to Ibrance (palbociclib) or Verzenio (abemaciclib), each with its own PAP, the manufacturer’s copay program for commercially insured patients, or independent foundations such as Susan G. Komen, Living Beyond Breast Cancer, PAN Foundation, or HealthWell Foundation. If we cannot find a path, you won’t be charged our service fee.
Take Control of Your Medication Costs
If you are struggling with the high cost of Kisqali, our team may be able to help you access assistance programs designed to make brand specialty CDK4/6 inhibitor therapy affordable. Check your eligibility today.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.